GHRP-6 is a synthetic six-amino-acid peptide in the growth hormone secretagogue class, developed across the 1980s and 1990s as an early tool for prompting the body to release its own growth hormone rather than supplying the hormone directly. The published record describes its core action as agonism at the ghrelin receptor GHS-R1a, the same receptor the hormone ghrelin binds, which triggers the anterior pituitary to release a pulse of stored growth hormone and drives a downstream rise in insulin-like growth factor 1. It remains a compound studied in laboratory and clinical research rather than an approved therapeutic in most jurisdictions.
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue that raises growth hormone by activating the ghrelin receptor GHS-R1a, and it carries no marketing approval as a therapeutic in most jurisdictions.
The class question has a precise answer in the chemistry literature: GHRP-6 is a synthetic hexapeptide, a chain of six amino acids, sitting in the pharmacological group called growth hormone secretagogues. Its sequence deliberately includes two unnatural D-configuration residues, D-tryptophan and D-phenylalanine, which resist the peptidase enzymes that would otherwise degrade an all-L peptide within minutes. The design traces to 1970s and 1980s work by Cyril Bowers, who refined secretagogue leads away from met-enkephalin's opioid activity and toward selective growth hormone release.
GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, a molecular formula of C46H56N12O6, and a molecular weight of approximately 873 daltons.
The stimulation the literature reports works on two levels of the hypothalamic-pituitary axis at once, not one. In the anterior pituitary GHRP-6 binds the Gq-coupled receptor GHS-R1a on somatotroph cells and drives a calcium-dependent release of stored growth hormone, while at the hypothalamus it raises growth hormone releasing hormone and lifts the inhibitory brake of somatostatin. Removing that brake at the same time as adding a releasing signal is a large part of why the reported pulse is so pronounced.
GHRP-6 releases growth hormone by binding the Gq-coupled receptor GHS-R1a on pituitary somatotrophs to raise intracellular calcium while simultaneously increasing growth hormone releasing hormone and suppressing somatostatin at the hypothalamus.
The ghrelin receptor is the linchpin of the molecule's biology. Formally the growth hormone secretagogue receptor type 1a, GHS-R1a is a G-protein-coupled receptor densest in the hypothalamus and pituitary but also present in the stomach, pancreas, and heart, and GHRP-6 is a synthetic agonist that activates it the way the body's own ghrelin does. A notable point of scientific history is that the receptor was found because of compounds like GHRP-6, cloned in 1996, with its natural ligand ghrelin isolated only afterward in 1999.
GHRP-6 is a synthetic agonist of the ghrelin receptor GHS-R1a, the receptor cloned in 1996 through work on such secretagogues before its natural ligand ghrelin was isolated in 1999.
The strong hunger reported with GHRP-6 is not a separate side effect but a direct consequence of the same receptor that drives its growth hormone release. When the compound binds GHS-R1a in the arcuate nucleus of the hypothalamus, it activates the orexigenic neurons that co-express neuropeptide Y and agouti-related peptide, the brain's core appetite circuitry. Because both the hunger and the growth hormone signal flow from one receptor, the appetite effect is essentially inseparable from the compound's primary action, and it scales with dose.
GHRP-6 increases hunger because it activates the same arcuate-nucleus GHS-R1a receptor and NPY/AgRP neurons that the appetite hormone ghrelin uses, giving it the most pronounced appetite signature among ghrelin-receptor secretagogues.
The defining difference is the receptor each compound targets. Growth hormone releasing hormone and its analogues sermorelin and tesamorelin act on the GHRH receptor, while GHRP-6 acts on the separate ghrelin receptor GHS-R1a, which is why pairing the two produces a growth hormone pulse larger than either alone. Among the ghrelin-receptor secretagogues themselves, GHRP-6 is the oldest and carries the most appetite stimulation, and the cleaner profiles of later molecules are why it was largely superseded as a first-choice research compound.
| Criteria | GHRP-6 | Ipamorelin |
|---|---|---|
| Receptor | GHS-R1a (ghrelin) | GHS-R1a (ghrelin) |
| Appetite effect | Marked increase | Minimal |
| Cortisol/prolactin | Can rise at higher doses | Little effect |
| GH potency | Lower, older lead | Higher selectivity |
GHRP-6 acts on the ghrelin receptor GHS-R1a rather than the GHRH receptor used by sermorelin and tesamorelin, and among ghrelin-receptor secretagogues it produces the strongest appetite, cortisol, and prolactin effects, which is why more selective analogues such as ipamorelin largely replaced it.
As a small peptide, GHRP-6 follows the pharmacokinetic rules that govern peptide drugs, and the published data reports it is not meaningfully active by mouth because digestive enzymes and first-pass metabolism degrade it before it reaches circulation. Research administration relies on injection, usually subcutaneous, after which growth hormone concentrations rise within minutes and peak around fifteen to thirty minutes. Its circulating half-life is short, on the order of a few tens of minutes, and clearance runs through proteolytic breakdown into inactive fragments handled by the kidneys rather than the cytochrome pathways that clear many small-molecule drugs.
GHRP-6 is inactive orally and is given by injection in research, producing a growth hormone peak at roughly 15 to 30 minutes with a circulating half-life of only a few tens of minutes before proteolytic clearance into inactive fragments.
Most of the lasting effects attributed to GHRP-6 are really the effects of the growth hormone it releases and of what that growth hormone in turn stimulates. The dominant downstream mediator is insulin-like growth factor 1, produced mainly by the liver, which carries out much of the anabolic signaling behind protein synthesis and tissue growth, while growth hormone itself drives lipolysis and opposes insulin. Separately, laboratory research has reported ghrelin-receptor effects in peripheral tissues, including cytoprotective and possible cardioprotective actions in models of ischemic injury that appear at least partly independent of growth hormone.
The sustained effects of GHRP-6 are carried mainly by the growth hormone it releases and by liver-derived IGF-1, which drive anabolic and lipolytic signaling, while growth hormone's insulin-opposing action can raise blood glucose under prolonged elevation.
GHRP-6 holds no marketing approval as a therapeutic from major regulators such as the United States Food and Drug Administration or the European Medicines Agency, and it is handled as a research chemical rather than an approved medicine. It has been studied for decades as a diagnostic and experimental probe of pituitary function and still appears in preclinical work, including research on its ghrelin-receptor tissue-protective effects. In competitive sport it is unambiguously banned, and material sold under its name is typically labeled for laboratory research use only, not for human consumption.
GHRP-6 has no FDA or EMA marketing approval and is treated as a research chemical, and the World Anti-Doping Agency prohibits it at all times under class S2 as a growth hormone releasing factor.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-6. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
